Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women

References

• AdamiSFelsenbergDChristiansenC2004Efficacy and safety of ibandronate given by intravenous injection once every 3 monthsBone34881915121020
   PubMed Web of Science ®Google Scholar
• BarrettJWorthEBaussF2004Ibandronate: a clinical pharmacological and pharmacokinetic updateJ Clin Pharmacol449516515317823
   PubMed Web of Science ®Google Scholar
• BaussFRussellRG2004Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosingOsteoporos Int154233315205712
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMR2003Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol14139940512954579
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJTripathyD2006Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial resultsEur J Cancer Care15299302
   PubMed Web of Science ®Google Scholar
• BodyJJLichinitserMAndreevaN2004Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: Results of an open-label studyJ Clin Oncol2260S
   Web of Science ®Google Scholar
• BounameauxHMSchifferliJMontaniJP1983Renal failure associated with intravenous diphosphonatesLancet14716131186
   PubMed Web of Science ®Google Scholar
• BrownJPKendlerDLMcClungMR2002The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int711031112085156
   PubMed Web of Science ®Google Scholar
• ChesnutCHSkagAChristiansenC2004Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res191241915231010
   PubMed Web of Science ®Google Scholar
• ChristiansenCTankoLBWarmingL2003Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronateOsteoporos Int146091312830369
   PubMed Web of Science ®Google Scholar
• DelmasPDAdamiSStrugalaC2006Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA studyArthritis Rheum5418384616729277
   PubMed Web of Science ®Google Scholar
• DumonJCMagritteABodyJJ1991Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemiaBone Miner15257661773138
   PubMedGoogle Scholar
• EismanJGarcia-HernandezPOrtiz-LunaG2006Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from DIVAOsteoporos Int17Suppl. 2S212[abstract P316SA].
   Google Scholar
• LyubimovaNVKushlinskyNELichinitserM2003Long-term treatment with intravenous ibandronate does not effect renal function in breast cancer patients with metastatic bone diseaseSupport Care Cancer11416[abstract A–107].
   Google Scholar
• MühlbauerRCBaussFSchenkR1991BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJ Bone Miner Res61003111838661
   PubMed Web of Science ®Google Scholar
• NeugebauerGKoehlerWAkinkunmiL2001Influence of peak ibandronic acid concentrations after 6 mg i.v. administration with shortened infusion time (15 and 30 minutes) on renal safety in manProc Am Soc Clin Oncol20122A[abstract 486].
   Google Scholar
• O’SullivanTLAkbariACadnapaphornchaiP1994Acute renal failure associated with the administration of parenteral etidronateRen Fail16767737899588
   PubMed Web of Science ®Google Scholar
• PecherstorferMDielIJ2004Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancySupport Care Cancer128778115372222
   PubMed Web of Science ®Google Scholar
• PecherstorferMSteinhauerEURizzoliR2003Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronateSuppor Care Cancer1153947
   PubMed Web of Science ®Google Scholar
• PfisterTAtzpodienEBaussF2003The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in ratsToxicology1911596712965119
   PubMed Web of Science ®Google Scholar
• ReckerRRStakkestadJChesnutC2004Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosisBone34890915121021
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFaberH2003Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative studyOsteoporos Int14801714610641
   PubMed Web of Science ®Google Scholar
• SchimmerRCBaussF2003Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studiesClin Ther25193412637110
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiG2000Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)1211210746426
   PubMedGoogle Scholar
• SmithSYReckerRRHannanM2003Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeysBone32455512584035
   PubMed Web of Science ®Google Scholar
• StakkestadJABenevolenskayaLIStepanJJ2003Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal womenAnn Rheum Dis629697512972476
   PubMed Web of Science ®Google Scholar
• ThiébaudDBurckhardtPKriegbaumH1997Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosisAm J Med1032983079382122
   PubMed Web of Science ®Google Scholar